Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021, with a specific transaction date of July 28, 2021. The report serves as a transaction notification regarding share allocations for Non-Executive Directors under the company's share allocation arrangements for the service period of April 1, 2021, to June 30, 2021.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific equity transactions involving the following instruments and prices:
- Ordinary Shares (GBP): Priced at £14.05 per share (ISIN: GB0009252882).
- American Depositary Shares (USD): Priced at $39.35 per ADS (ISIN: US37733W1053).
Material Changes
The filing reports no material changes to the company's financial position or operations. It documents the acquisition of notional shares by the following Persons Discharging Managerial Responsibilities (PDMRs):
- Sir Jonathan Symonds (Non-Executive Chairman): Acquired 3,113.879 Ordinary Shares.
- Mr Charles Bancroft (Independent Non-Executive Director): Acquired 1,469.711 ADSs.
- Mr Vindi Banga (Senior Independent Non-Executive Director): Acquired 645.018 Ordinary Shares.
- Dr Anne Beal (Independent Non-Executive Director): Acquired 122.409 ADSs.
- Dr Vivienne Cox (Independent Non-Executive Director): Acquired 600.534 Ordinary Shares.
- Ms Lynn Elsenhans (Independent Non-Executive Director): Acquired 283.444 ADSs.
- Dr Laurie Glimcher (Independent Non-Executive Director): Acquired 1,049.794 ADSs.
- Dr Jesse Goodman (Independent Non-Executive Director): Acquired 346.432 ADSs.
- Mr Urs Rohner (Independent Non-Executive Director): Acquired 572.183 Ordinary Shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of director share transactions.
Investor Verification Checklist
- Verify the total number of shares/ADSs allocated to Non-Executive Directors for the Q2 2021 service period.
- Confirm the transaction price of £14.05 for Ordinary Shares and $39.35 for ADSs against market prices on July 28, 2021.
- Review the company's broader 20-F or 40-F filings for consolidated financial performance, as this 6-K contains no operational data.
- Check for any subsequent filings regarding the vesting or settlement of these notional share allocations.